TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01912118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
Study: NCT00443651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was supplied as a concentrate for IV administration at a concentration of 10 mg/mL in 500 mg (50 mL) single-use vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was supplied as a concentrate for IV administration at a concentration of 10 mg/mL in 500 mg (50 mL) single-use vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drugs
Description: Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drugs
Description: Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).
Study: NCT06559904

Intervention type: OTHER
Group type: OTHER
Intervention: Mediterranean diet
Description: The 'Mediterranean Diet Education Document', prepared by the researcher, which includes general information about the characteristics of the Mediterranean diet and the portion sizes that should be followed daily and weekly, and information on how often, how much and when to consume food groups, was provided as a diet education, and information was provided on how to record three-day food consumption.~A nutrition education compatible with the Mediterranean diet, organized by the researcher according to the individual's daily needs, was provided and a sample menu was explained to the individual face to face.
Study: NCT02875392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 275mg Oligo Fucoidan + 275mg HS Fucoxanthin
Description: Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo pills
Description: taking placebo pills as if patients are under treatment.
Study: NCT01175135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 5 mg tablet every 12 hours for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 15 mg tablet every 12 hours for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet/capsule every 12 hours for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 3 mg capsule every 12 hours for 28 days
Study: NCT02641444

Intervention type: PROCEDURE
Intervention: Blood plasma collection
Description: Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.

Intervention type: PROCEDURE
Intervention: Blood plasma collection
Description: Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.

Intervention type: PROCEDURE
Intervention: Blood plasma collection
Description: Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.

Intervention type: PROCEDURE
Intervention: Blood plasma collection
Description: Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.

Intervention type: PROCEDURE
Intervention: Cervical and Vaginal Biopsy
Description: 2 biopsies each will be collected from the vaginal wall and the cervix

Intervention type: PROCEDURE
Intervention: Cervical and Vaginal Biopsy
Description: 2 biopsies each will be collected from the vaginal wall and the cervix

Intervention type: PROCEDURE
Intervention: Cervical and Vaginal Biopsy
Description: 2 biopsies each will be collected from the vaginal wall and the cervix

Intervention type: PROCEDURE
Intervention: Cervical and Vaginal Biopsy
Description: 2 biopsies each will be collected from the vaginal wall and the cervix

Intervention type: PROCEDURE
Intervention: Colonoscopy with Ileal and Rectal Biopsy
Description: 10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.

Intervention type: PROCEDURE
Intervention: Colonoscopy with Ileal and Rectal Biopsy
Description: 10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.

Intervention type: PROCEDURE
Intervention: Colonoscopy with Ileal and Rectal Biopsy
Description: 10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.

Intervention type: PROCEDURE
Intervention: Colonoscopy with Ileal and Rectal Biopsy
Description: 10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.
Study: NCT04476511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: tablet containing 30.000IU cholecalciferol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: tablet containing 30.000IU cholecalciferol
Study: NCT00834418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg Tablets
Description: 1 x 20 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARAVA™ 20 mg Tablets
Description: 1 x 20 mg, single-dose fasting
Study: NCT01242098

Intervention type: DRUG
Intervention: Fixed dose combination salmeterol / fluticasone
Description: Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy

Intervention type: DRUG
Intervention: Fixed-dose combination beclometasone dipropionate / formoterol
Description: Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
Study: NCT01910038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticoids+ tocilizumab 8mg/Kg/4 weeks
Study: NCT01895764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26
Study: NCT05125900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proximal box elevation using one of the tested materials
Description: Each patient randomly received deep proximal margin elevation with one of the tested restorative materials, while the overlying restorations were all the same regular bulk fill resin composite

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Proximal box elevation using one of the tested materials
Description: Each patient randomly received deep proximal margin elevation with one of the tested restorative materials, while the overlying restorations were all the same regular bulk fill resin composite

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Proximal box elevation using one of the tested materials
Description: Each patient randomly received deep proximal margin elevation with one of the tested restorative materials, while the overlying restorations were all the same regular bulk fill resin composite

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proximal box elevation using one of the tested materials
Description: Each patient randomly received deep proximal margin elevation with one of the tested restorative materials, while the overlying restorations were all the same regular bulk fill resin composite
Study: NCT03410784

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks up to 22 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 i.v. on Day 1 every 3 weeks up to 6 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Carboplatin (AUC 5) i.v. on Day 1 every 3 weeks for up to 6 cycles
Study: NCT02552758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: omega-3 fatty acid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positron emission tomography (PET)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: positron emission tomography (PET)
Study: NCT02163382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurovent Monitor XIII
Description: Nasogastric tiube installation to monitor EAdi

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurovent Monitor XIII
Description: RIP jacket installation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurovent Monitor XIII
Description: Ventilator change (if a different ventilator was used prior to the study).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurovent Monitor XIII
Description: Determination of NAVA parametersVentilator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurovent Monitor XIII
Description: Second period with conventional NIV settings
Study: NCT00926835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: 6 weeks, 20-50mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10-20mg/day for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR
Description: Venlafaxine 75-225mg/day for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine+Bupropion
Description: paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine+Lamotrigine
Description: Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine+Lithium
Description: Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram+Mirtazapine
Description: escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram+Aripiprazole
Description: escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
Study: NCT01851369

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Tumor biopsies will be optional during the escalation phase.
Study: NCT02966925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellular Matrix BCT-HA Kit
Description: Submucosal injections in the vulva, in the posterior vaginal wall and in the perineum of a combination product made of PRP and HA prepared using the Cellular Matrix BCT-HA medical device
Study: NCT00940459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senofilcon A contact lens (Acuvue Oasys)
Description: Silicone hydrogel contact lens CE-marked for the intended usage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfilcon A contact lens (Biofinity)
Description: Silicone hydrogel contact lens CE-marked for the intended usage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens (Air Optix)
Description: Silicone hydrogel contact lens CE-marked for the intended usage.
Study: NCT00926835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine + Venlafaxine XR
Description: Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
Study: NCT00940459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balafilcon A contact lens (PureVision)
Description: Silicone hydrogel contact lens CE-marked for the intended usage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lens (Acuvue 2)
Description: Hydrogel contact lens CE-marked for the intended usage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lens care system (EasySept)
Description: Contact lens care system CE-marked for the intended usage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens care system (EasySept)
Description: Contact lens care system CE-marked for the intended usage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens care system (EasySept)
Description: Contact lens care system CE-marked for the intended usage.
Study: NCT00831103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPB-348
Description: Treated over seven days
Study: NCT01912118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
Study: NCT01774448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: In the experimental condition, individuals with dementia (n = 15) and their spouses (n = 15) will partake in one MBCT session per week for 8 weeks. The partners will attend separate MBCT sessions (different day of the week). In the control condition, individuals with dementia (n = 15) and their spouses (n= 15) will go through an 8-week waitlist control period.
Study: NCT01251523

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PACE
Description: The first intervention to be tested, Physician Asthma Care Education (PACE), is a rigorously evaluated intervention for physicians that has reached hundreds of clinicians across the U.S. and also has been implemented in the United Kingdom and Australia. The efficacy trial of PACE was supported by the National Heart, Lung and Blood Institute and the effectiveness trial by the Robert Wood Johnson Foundation. PACE is now widely available to clinicians, through, among other channels, the National Asthma Education and Prevention Program (NAEPP). It is designed to enhance physician communication, counseling and therapeutics for assisting the general population of children with asthma.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PACE Plus
Description: In the PACE PLUS intervention a cultural competence component will be added to the PACE curriculum. The cultural competence component uses mini-lecture, video demonstration (video to be developed as part of this proposal), case studies and self observation tools to present the principles of cultural competence derived from the study of the literature. The component integrates into the skills taught, specific content related to working with African American and Puerto Rican families where a child has asthma.
Study: NCT00881205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Description: Transdermalapplication of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. All patches are round, beige in color.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
Study: NCT00940459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens care system (EasySept)
Description: Contact lens care system CE-marked for the intended usage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens care system (EasySept)
Description: Contact lens care system CE-marked for the intended usage.
Study: NCT03902990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task
Description: The patients in the dual task group received cognitive tasks during treadmill training sessions.
Study: NCT00550238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin tartrate (ACP-103)
Description: Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
Study: NCT00640783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: The dietary advice was tailored to each patient on the basis of 3-day food records. The recommended composition of the dietary regimen was as follows: carbohydrates, 50% to 60%; proteins, 15% to 20%; total fat, less than 30%; saturated fat, less than 10%; and cholesterol consumption, less than 300 mg per day. Moreover, patients were advised to consume at least 250 to 300 g of fruits, 125 to 150 g of vegetables, and 25 to 50 g of walnuts per day; in addition, they were also encouraged to consume 400 g of whole grains (legumes, rice, maize, and wheat) daily and to increase their consumption of olive oil.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients consuming the control diet were given general oral and written information about healthy food choices at baseline and at subsequent visits but were offered no specific individualized program. However, the general recommendation for macronutrient composition of the diet was similar to that for the intervention group (carbohydrates, 50%-60%; proteins, 15%-20%; and total fat, \<30%).
Study: NCT00831103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPB-348
Description: Treated over seven days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPB-348
Description: Treated over seven days
Study: NCT02651181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLCL- Hybrid Logic Closed Loop System
Description: All subjects wearing the HLCL System and using it with the closed loop algorithm
Study: NCT00849888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serum Free Thymus Transplantation with Immunosuppression
Description: Cyclosporine pre-transplant (trough 180-220ng/ml) until naive T cells develop. Subjects \>4,000/cumm T cells, pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day. All subjects pre-transplant days -5,-4,-3: 3 doses 2mg/kg rabbit anti-thymocyte globulin. Thymus tissue (unrelated donor), donor, \& donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects, FBS cultured thymus is transplanted in 1 leg \& serum free (SF) in other. After first 2 subjects \>10% naïve T cells, 3rd receives only SF thymus. After 3rd subject \>10%naive T cells, 4th subject transplanted. Thymus dose 4-18 grams/m2 body surface area. Thymus biopsy 8-12 weeks post-transplant. Skin biopsy at time of transplant \& thymus biopsy. Followed by immune evaluations.
Study: NCT00831103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: Treated over seven days
Study: NCT04562935

Intervention type: OTHER
Intervention: admission to pediatric intensive care with mechanical ventilation
Description: admission to pediatric intensive care with mechanical ventilation
Study: NCT01904162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg finafloxacin (2 x 200 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg finafloxacin (2 x 200 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg finafloxacin (2 x 200 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg finafloxacin (2 x 200 mg tablets)
Study: NCT00849888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum Free Thymus Transplantation without immunosuppression
Description: Thymus tissue (unrelated donor), donor, \& donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects: FBS cultured thymus transplanted in 1 leg \& serum free cultured thymus in other leg. After first 2 subjects have thymopoiesis in serum-free biopsy, \>10% naïve T cells, 3rd subject receives only serum free cultured thymus. After 3rd subject \>10% naive T cells, 4th subject receives transplant of only serum free cultured thymus. Dose 4-18grams/m2 body surface area. At time of transplant, skin biopsy. Allograft biopsy \& skin biopsy done 8 to 12 weeks post-transplant. (Graft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples, for two years.